129 related articles for article (PubMed ID: 2960430)
1. Cerebral glucose and dopa metabolism in movement disorders.
Martin WR; Hayden MR
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):448-51. PubMed ID: 2960430
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of regional cerebral glucose metabolism.
Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M
Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938
[TBL] [Abstract][Full Text] [Related]
3. Regional cerebral glucose metabolism differs in adult and rigid juvenile forms of Huntington disease.
Matthews PM; Evans AC; Andermann F; Hakim AM
Pediatr Neurol; 1989; 5(6):353-6. PubMed ID: 2532511
[TBL] [Abstract][Full Text] [Related]
4. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
[TBL] [Abstract][Full Text] [Related]
5. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
Kuhl DE; Metter EJ; Riege WH; Markham CH
Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
[TBL] [Abstract][Full Text] [Related]
6. [Functional imaging for disorders of basal ganglia].
Otsuka M; Taniwaki T
Rinsho Shinkeigaku; 1999 Jan; 39(1):30-2. PubMed ID: 10377793
[TBL] [Abstract][Full Text] [Related]
7. Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome.
Przedborski S; Giladi N; Takikawa S; Ishikawa T; Dhawan V; Spetsieris P; Chaly T; Fahn S; Eidelberg D
Neurology; 1994 Sep; 44(9):1622-8. PubMed ID: 7936286
[TBL] [Abstract][Full Text] [Related]
8. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
9. [A case of familial juvenile dystonia-parkinsonism: 18F-6-fluorodopa and 18F-fluoro-2-deoxyglucose PET study].
Hanakawa T; Fukuyama H; Akiguchi I; Kato M; Kimura J; Shibasaki H
Rinsho Shinkeigaku; 1996 May; 36(5):655-60. PubMed ID: 8905984
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.
Berent S; Giordani B; Lehtinen S; Markel D; Penney JB; Buchtel HA; Starosta-Rubinstein S; Hichwa R; Young AB
Ann Neurol; 1988 Jun; 23(6):541-6. PubMed ID: 2970247
[TBL] [Abstract][Full Text] [Related]
11. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.
Martin WR; Stoessl AJ; Adam MJ; Ammann W; Bergstrom M; Harrop R; Laihinen A; Rogers JG; Ruth TJ; Sayre CI
Adv Neurol; 1987; 45():95-8. PubMed ID: 3103398
[No Abstract] [Full Text] [Related]
13. Positron emission tomography in movement disorders.
Martin WR
Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662
[TBL] [Abstract][Full Text] [Related]
14. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
[TBL] [Abstract][Full Text] [Related]
15. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
[TBL] [Abstract][Full Text] [Related]
16. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
17. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.
Kuhl DE; Phelps ME; Markham CH; Metter EJ; Riege WH; Winter J
Ann Neurol; 1982 Nov; 12(5):425-34. PubMed ID: 6217782
[TBL] [Abstract][Full Text] [Related]
18. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
Leenders KL; Frackowiak RS; Quinn N; Marsden CD
Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
[TBL] [Abstract][Full Text] [Related]
19. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
[TBL] [Abstract][Full Text] [Related]
20. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET).
De Volder A; Bol A; Michel C; Cogneau M; Evrard P; Lyon G; Goffinet AM
Brain Dev; 1988; 10(1):47-50. PubMed ID: 2967038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
